Additionally, based on the assessment of correlation between gain-of-function or loss-of-function mutations in cancer genes bearing recurrent somatic structural mutations in our cohort (CNVs and SVs) and gene expression values (TPMs), we identified significant correlation of low SETD2 expression with somatic SETD2 mutations (p = 0.0003) as well as significant correlation of increased MYC expression with somatic MYC copy number gains (p = 0.018). Here, SETD2 is linked to cancer.